Tag: daratumumab

1. Daratumumab therapy addition to bortezomib, cyclophosphamide, and dexamethasone showed improved cancer response in patients with systemic immunoglobulin light-chain amyloidosis. 2. The daratumumab group presented with an increase in serious adverse events such as lymphopenia, cardiac failure, and infections. Evidence Rating Level: 1 (Excellent) Study Rundown: Immunoglobulin light-chain amyloidosis (AL) is a...